Fekade Bruck Sime1, Michael S Roberts2, Ing Soo Tiong3, Julia H Gardner4, Sheila Lehman4, Sandra L Peake5, Uwe Hahn4, Morgyn S Warner6, Jason A Roberts7. 1. School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia Therapeutics Research Centre, Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Adelaide, Australia fekade.sime@mymail.unisa.edu.au. 2. School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia Therapeutics Research Centre, Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Adelaide, Australia Therapeutics Research Centre, School of Medicine, University of Queensland, Brisbane, Australia. 3. Department of Haematology/Oncology, The Queen Elizabeth Hospital, Adelaide, Australia SA Pathology and the University of Adelaide, Adelaide, Australia. 4. Department of Haematology/Oncology, The Queen Elizabeth Hospital, Adelaide, Australia. 5. Department of Intensive Care Medicine, The Queen Elizabeth Hospital, Adelaide, Australia. 6. SA Pathology and the University of Adelaide, Adelaide, Australia. 7. School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia Royal Brisbane and Women's Hospital, Herston, Brisbane, Queensland, Australia Burns, Trauma, and Critical Care Research Centre, University of Queensland, Herston, Brisbane, Queensland, Australia Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Abstract
OBJECTIVES: The objectives of this study were to describe piperacillin exposure in febrile neutropenia patients and determine whether therapeutic drug monitoring (TDM) can be used to increase the achievement of pharmacokinetic (PK)/pharmacodynamic (PD) targets. METHODS: In a prospective randomized controlled study (Australian New Zealand Registry, ACTRN12615000086561), patients were subjected to TDM for 3 consecutive days. Dose was adjusted in the intervention group to achieve a free drug concentration above the MIC for 100% of the dose interval (100% fT>MIC), which was also the primary outcome measure. The secondary PK/PD target was 50% fT>MIC. Duration of fever and days to recovery from neutropenia were recorded. RESULTS:Thirty-two patients were enrolled. Initially, patients received 4.5 g of piperacillin/tazobactam every 8 h or every 6 h along with gentamicin co-therapy in 30/32 (94%) patients. At the first TDM, 7/32 (22%) patients achieved 100% fT>MIC and 12/32 (38%) patients achieved 50% fT>MIC. Following dose adjustment, 11/16 (69%) of intervention patients versus 3/16 (19%) of control patients (P = 0.012) attained 100% fT>MIC, and 15/16 (94%) of intervention patients versus 5/16 (31%) of control patients (P = 0.001) achieved 50% fT>MIC. After the third TDM, the proportion of patients attaining 100% fT>MIC improved from a baseline 3/16 (19%) to 11/15 (73%) in the intervention group, while it declined from 4/16 (25%) to 1/15 (7%) in the control group. No difference was noted in the duration of fever and days to recovery from neutropenia. CONCLUSIONS: Conventional doses of piperacillin/tazobactam may not offer adequate piperacillin exposure in febrile neutropenic patients. TDM provides useful feedback of dosing adequacy to guide dose optimization.
RCT Entities:
OBJECTIVES: The objectives of this study were to describe piperacillin exposure in febrile neutropeniapatients and determine whether therapeutic drug monitoring (TDM) can be used to increase the achievement of pharmacokinetic (PK)/pharmacodynamic (PD) targets. METHODS: In a prospective randomized controlled study (Australian New Zealand Registry, ACTRN12615000086561), patients were subjected to TDM for 3 consecutive days. Dose was adjusted in the intervention group to achieve a free drug concentration above the MIC for 100% of the dose interval (100% fT>MIC), which was also the primary outcome measure. The secondary PK/PD target was 50% fT>MIC. Duration of fever and days to recovery from neutropenia were recorded. RESULTS: Thirty-two patients were enrolled. Initially, patients received 4.5 g of piperacillin/tazobactam every 8 h or every 6 h along with gentamicin co-therapy in 30/32 (94%) patients. At the first TDM, 7/32 (22%) patients achieved 100% fT>MIC and 12/32 (38%) patients achieved 50% fT>MIC. Following dose adjustment, 11/16 (69%) of intervention patients versus 3/16 (19%) of control patients (P = 0.012) attained 100% fT>MIC, and 15/16 (94%) of intervention patients versus 5/16 (31%) of control patients (P = 0.001) achieved 50% fT>MIC. After the third TDM, the proportion of patients attaining 100% fT>MIC improved from a baseline 3/16 (19%) to 11/15 (73%) in the intervention group, while it declined from 4/16 (25%) to 1/15 (7%) in the control group. No difference was noted in the duration of fever and days to recovery from neutropenia. CONCLUSIONS: Conventional doses of piperacillin/tazobactam may not offer adequate piperacillin exposure in febrile neutropenicpatients. TDM provides useful feedback of dosing adequacy to guide dose optimization.
Authors: Fekade Bruck Sime; Uwe Hahn; Morgyn S Warner; Ing Soo Tiong; Michael S Roberts; Jeffrey Lipman; Sandra L Peake; Jason A Roberts Journal: Antimicrob Agents Chemother Date: 2017-10-24 Impact factor: 5.191
Authors: Fekade Bruck Sime; Michael S Roberts; Ing Soo Tiong; Julia H Gardner; Sheila Lehman; Sandra L Peake; Uwe Hahn; Morgyn S Warner; Jason A Roberts Journal: Antimicrob Agents Chemother Date: 2015-06-29 Impact factor: 5.191
Authors: Tobias Rachow; Verena Schlüter; Sibylle Bremer-Streck; Udo Lindig; Sebastian Scholl; Peter Schlattmann; Michael Kiehntopf; Andreas Hochhaus; Marie von Lilienfeld-Toal Journal: Infection Date: 2017-05-17 Impact factor: 3.553
Authors: J Laporte-Amargos; C Gudiol; M Arnan; P Puerta-Alcalde; F Carmona-Torre; M Huguet; A Albasanz-Puig; R Parody; C Garcia-Vidal; J L Del Pozo; M Batlle; C Tebé; R Rigo-Bonnin; C Muñoz; A Padullés; F Tubau; S Videla; A Sureda; J Carratalà Journal: Trials Date: 2020-05-18 Impact factor: 2.279
Authors: Pier Giorgio Cojutti; Davide Lazzarotto; Anna Candoni; Maria Vittoria Dubbini; Maria Elena Zannier; Renato Fanin; Federico Pea Journal: J Antimicrob Chemother Date: 2020-10-01 Impact factor: 5.790
Authors: Pascal André; Léonore Diezi; Kim Dao; Pierre Alex Crisinel; Laura E Rothuizen; Haithem Chtioui; Laurent Arthur Decosterd; Manuel Diezi; Sandra Asner; Thierry Buclin Journal: Front Pediatr Date: 2022-01-05 Impact factor: 3.418
Authors: Stefan Hagel; Friedhelm Bach; Thorsten Brenner; Hendrik Bracht; Alexander Brinkmann; Thorsten Annecke; Andreas Hohn; Markus Weigand; Guido Michels; Stefan Kluge; Axel Nierhaus; Dominik Jarczak; Christina König; Dirk Weismann; Otto Frey; Dominic Witzke; Carsten Müller; Michael Bauer; Michael Kiehntopf; Sophie Neugebauer; Thomas Lehmann; Jason A Roberts; Mathias W Pletz Journal: Intensive Care Med Date: 2022-02-01 Impact factor: 41.787